Company news

Therma Bright Inc. news in 2021

Therma Bright Inc.'s news releases, calls and decks from 2021, newest first.

View company

Therma Bright AcuVid(TM) COVID-19 Rapid Antigen Saliva Test's Antibodies Successfully Detect the COVID-19 Omicron B.1.1.529 Variant

December 16, 2021

Therma Bright Expands Manufacturing Capabilities To Meet New FDA EUA Guidance For AcuVid(TM)

December 1, 2021

Therma Bright Launches Benepod.com eCommerce Website

November 24, 2021

Therma Bright to Begin AcuVid(TM) U.S. Clinical Performance Study with Receipt of IRB Conditional Approval

November 12, 2021

Therma Bright Provides Update on FDA-EUA Application Process

October 28, 2021

Therma Bright Provides Update for its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test

October 4, 2021

Therma Bright Successfully Up-lists to the OTCQB Venture Market Under Symbol TBRIF

September 14, 2021

Therma Bright Enters into Securities for Services Agreement, Debt Settlement, and Issues Options

August 12, 2021

Therma Bright Finalizes Agreement with Afero for Its Smart-Enabled AcuVid(TM) Saliva Test

August 5, 2021

Therma Bright Files Application to the OTCQB and DTC Clearing

July 29, 2021

Therma Bright Awaits FDA-EUA Approval From Over 260 AcuVid(TM) Clinical Study Test Results

July 22, 2021

Therma Bright's AcuVid(TM) COVID-19 Rapid Antigen Saliva Test Successfully Detects the COVID-19 Delta Variant Strain

July 8, 2021

Therma Bright Secures US Distributor 'DME Authority' for Its Patented Venowave Lightweight Deep Vein Thrombosis (DVT) Device, Just as US Healthcare Providers Deal with Device Shortages

June 28, 2021

Therma Bright to Test AcuVid(TM) on the Highly Contagious COVID-19 Delta Variant, Company Completes Brazilian Clinical Study for Final FDA EUA Submission

June 24, 2021

Therma Bright Reports Performance of Its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test from Brazilian Clinical Study

June 17, 2021

Therma Bright Provides Update on Brazilian Clinical Study

May 27, 2021

Therma Bright Secures Development and Manufacturing Partner for AcuVid(TM) COVID-19 Rapid Antigen Saliva Test

May 21, 2021

Therma Bright Enters into Agreement to Distribute a 15 Minute Rapid COVID-19 Antibody Test

May 6, 2021

Therma Bright Partners With Afero To Make AcuVid(TM) COVID-19 Rapid Antigen Saliva Test Smart-Enabled

April 28, 2021

Therma Bright's AcuVid(TM) COVID-19 Rapid Antigen Saliva Test Detects the Important SARS-CoV-2 Variants of Concern; the Brazilian P.1 and P.2 and the UK B.1.1.7 Variants

April 22, 2021

Therma Bright Announces EU-CE Approval for AcuVid(TM) COVID-19 Rapid Antigen Saliva Test and Conditional Sale for 100,000 CE-only AcuVid(TM) Test Kits

April 19, 2021

Therma Bright Provides Update on Brazilian Performance Study of its AcuVid(TM) COVID-19 Rapid Saliva-Based Antigen Test

April 13, 2021

Therma Bright Receives IRB Approval and Submits Application to Health Canada to Begin Clinical Study for its AcuVid(TM) COVID-19 Rapid Saliva-Based Antigen Test

March 25, 2021

Therma Bright Partners with Ridge Global to Expand Its United States and Global Reach

March 24, 2021

Therma Bright Initiates Clinical Performance Study in Brazil for its AcuVid(TM) COVID-19 Rapid Saliva-Based Antigen Test

March 18, 2021

Therma Bright Submits Application to Research Ethics Board for Approval of Clinical Trials for AcuVid(TM) COVID-19 Rapid Saliva-Based Antigen Test

March 11, 2021

Therma Bright Enters into Clinical Trial Agreement for its AcuVid(TM) COVID-19 Rapid Saliva-Based Antigen Test

February 26, 2021

Therma Bright Adds $1,171,875 to Treasury Through Exercise of Warrants and Options

January 29, 2021

Therma Bright Acquires 100% Control of its COVID-19 Rapid Saliva Antigen Test and Announces Proposed Name Change for the Test

January 25, 2021

Therma Bright Reports Improved Accuracy For Its COVID-19 Rapid Saliva Antigen Test, CoviSafeTM, And Prepares For Prospective Studies

January 18, 2021

Therma Bright Adds Veteran Manufacturing Expert to Advisory Team to Advance its Saliva-Based Rapid Antigen Test CoviSafe(TM)

January 15, 2021